Biocryst Pharmaceuticals (BCRX) Total Debt Growth (3y) (2014 - 2026)
Biocryst Pharmaceuticals (BCRX) Total Debt Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -7.03% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.29% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -58.89% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -12.80% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 72.82% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -4.66% |
| 10 | Biocryst Pharmaceuticals | 2.02 Bn | 1.78 Bn | 151.04 Mn | 23.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.27% |
| Dec 31, 2025 | -45.04% |
| Sep 30, 2025 | 1.20% |
| Jun 30, 2025 | 24.45% |
| Mar 31, 2025 | 35.61% |
| Dec 31, 2024 | 36.69% |
| Sep 30, 2024 | 38.04% |
| Jun 30, 2024 | 39.31% |
| Mar 31, 2024 | 39.57% |
| Dec 31, 2023 | 39.75% |
| Sep 30, 2023 | 86.36% |
| Mar 31, 2023 | 66.32% |
| Dec 31, 2022 | 66.36% |
| Sep 30, 2022 | 64.73% |
| Jun 30, 2022 | 42.59% |
| Mar 31, 2022 | 41.39% |
| Dec 31, 2021 | 65.62% |
| Sep 30, 2021 | 64.04% |
| Jun 30, 2021 | 85.08% |
| Mar 31, 2021 | 78.56% |